# Ceryx Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceryx-medical

- Industry: Medical Devices & Equipment
- Headquarters: Cardiff, UK
- Website: www.ceryxmedical.com
- Total disclosed funding: $12M
- Latest round: Series A (Jun 10, 2025)
- Investors on record: 6

## About

Ceryx Medical Ltd. is a medical technology company focused on developing bioelectronic devices for heart failure patients, aiming to improve cardiac performance and quality of life through innovative solutions.Founded in 2016 and headquartered in Cardiff, UK, Ceryx Medical Ltd. specializes in bioelectronic medical devices. The founders of the company are Alain Nogaret and Julian Paton, with Stuart Plant serving as the CEO. Ceryx Medical Ltd specializes in the development of innovative bioelectronic medical devices, with its flagship product being Cysoni, designed specifically for patients suffering from heart failure. Cysoni employs advanced biomimetic design principles and patented electronics to continuously monitor the patient's cardiorespiratory system, processing vital physiological signals to generate precisely timed impulses that optimize heartbeats. This technology aims to restore cardiac performance, alleviate symptoms such as breathlessness and exhaustion, and enhance the overall quality of life for users. The company targets healthcare providers and clinicians as primary customers, with end users being individuals diagnosed with heart failure and other related conditions. Ceryx's solutions are geared towards addressing significant health challenges in major global markets, including Europe, North America, and parts of Asia, where the prevalence of heart failure and associated healthcare expenditures are particularly high.Ceryx Medical Ltd operates on a model that involves direct sales of its bioelectronic devices to healthcare institutions and potentially individual patients through partnerships with medical professionals. The company’s revenue structure includes transactions that involve the provisioning of medical devices, such as Cysoni, which are integral to patient treatment plans. This allows healthcare providers to integrate Ceryx's technology into their patient care protocols, enhancing treatment options for heart failure management. Pricing strategies for their devices reflect the advanced technology and clinical benefits provided, aligning with healthcare budgets allocated for chronic disease management. The company's approach emphasizes the importance of effective treatment solutions in addressing the significant healthcare costs associated with heart failure, with revenue primarily derived from the sale and integration of these specialized medical devices into existing healthcare frameworks. In June 2025, Ceryx Medical Ltd. raised GBP 5 million in venture funding co-led by returning investors Parkwalk Advisors and Development Bank of Wales, with participation from another returning investor BGF. New investors BBI, Bristol Private Equity and other unspecified investors also participated in the round. The company plans to utilize the June 2025 funding to advance its technology and develop its clinical trials.

## Funding rounds

- Series A, Jun 10, 2025, $6.6M — BGF Investment Management, Development Bank of Wales, Parkwalk Advisors, Bristol Private Equity Club, BBI Capital
- Seed, Mar 31, 2022, $5M — BGF Investment Management, Development Bank of Wales, Parkwalk Advisors, Icehouse Ventures
- Seed, Jul 21, 2020, $0.7M — Development Bank of Wales, Parkwalk Advisors

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed, Series A
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Seed, Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Seed, Series A
- Icehouse Ventures (https://capitalatlas.ai/funds/icehouse-ventures) — Seed
- Bristol Private Equity Club (https://capitalatlas.ai/funds/bristol-private-equity-club) — Series A
- BBI Capital — Series A